AICDA and hematopoietic and lymphoid cell neoplasm: The combined AID-PRS was significantly associated with increased risks of hematological cancer (HR [95% CI] per SD increase: 1.06 [1.03–1.09]) and non-Hodgkin’s lymphoma (HR [95% CI] per SD increase: 1.10 [1.05–1.14]).